title: Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
abstract: OBJECTIVE
  This study was designed to determine the toxicity, radiographic response rate, and outcome following high-dose thiotepa, etoposide, and autologous bone marrow rescue (ABMR) for young patients with recurrent malignant brain tumors.
  
  
  METHODS
  Eligibility criteria required adequate renal, hepatic, and pulmonary function, and no bone marrow infiltration. Thiotepa 300 mg/m2 and etoposide 500 mg/ m2 were infused on 3 consecutive days, and autologous bone marrow was infused 72 hours following chemotherapy.
  
  
  RESULTS
  Forty-five patients with recurrent high-grade brain tumors, aged 8 months to 36 years (median, 8 years), were treated. Seven patients (16%) died of treatment-related toxicities within 56 days of marrow reinfusion. Delayed platelet engraftment occurred in 44% of patients who survived beyond day 56. Of 35 patients with radiographically measurable disease who survived at least 28 days following ABMR, there were two complete responses (CRs) and six partial responses (PRs), for an overall response (CRs plus PRs) rate of 23% (SE = 7%). Objective responses were observed in four of 14 assessable patients with high-grade glioma and in two of six with primitive neuroectodermal tumors (PNETs)/ medulloblastoma. Survival was significantly improved in patients treated with minimal residual disease (P < .0005). Five of 18 patients (28%) with high-grade gliomas remain free of disease at 39+, 44+, 49+, 52+, and 59+ months post-ABMR.
  
  
  CONCLUSIONS
  The combination of high-dose thiotepa and etoposide has activity against a variety of recurrent childhood brain tumors. These results merit further evaluation in children and young adults with both recurrent and newly diagnosed high-grade brain tumors.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Finlay
authors.forename: S
authors.initials: S
authors.lastname: Goldman
authors.forename: M C
authors.initials: MC
authors.lastname: Wong
authors.forename: M
authors.initials: M
authors.lastname: Cairo
authors.forename: J
authors.initials: J
authors.lastname: Garvin
authors.forename: C
authors.initials: C
authors.lastname: August
authors.forename: B H
authors.initials: BH
authors.lastname: Cohen
authors.forename: P
authors.initials: P
authors.lastname: Stanley
authors.forename: R A
authors.initials: RA
authors.lastname: Zimmerman
authors.forename: B
authors.initials: B
authors.lastname: Bostrom
authors.forename: J R
authors.initials: JR
authors.lastname: Geyer
authors.forename: R E
authors.initials: RE
authors.lastname: Harris
authors.forename: J
authors.initials: J
authors.lastname: Sanders
authors.forename: A J
authors.initials: AJ
authors.lastname: Yates
authors.forename: J M
authors.initials: JM
authors.lastname: Boyett
authors.forename: R J
authors.initials: RJ
authors.lastname: Packer
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007223:Infant; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000628:therapy*; D010865:Pilot Projects; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects; D014182:Transplantation, Autologous
chemical_list: D005047:Etoposide; D013852:Thiotepa